Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avalyn PharmaAVLN -1.01%11 3-1 Month Momentum % is -0.37% as of Aug. 04, 2026. GuruFocus rates AVLN with a GF Score™ of 11/100. Among 1,389 Biotechnology companies, Avalyn Pharma ranks better than 76.53% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-04), Avalyn Pharma's 3-1 Month Momentum % is -0.37%.
The industry rank for Avalyn Pharma's 3-1 Month Momentum % or its related term are showing as below:
AVLN's 3-1 Month Momentum % is ranked better than 76.53% of 1389
companies
in the Biotechnology industry
Industry Median: -7.65
vs AVLN: -0.37
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Avalyn Pharma 3-1 Month Momentum % Related Terms
AVLN vs TRAX, IMTX, ARDX: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Avalyn Pharma's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avalyn Pharma 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avalyn Pharma's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Avalyn Pharma's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma (AVLN) has a 3-1 Month Momentum % of -0.37% as of Aug. 04, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Avalyn Pharma and its competitors. According to the industry distribution chart, Avalyn Pharma ranks #326 out of 1389 companies in the Biotechnology industry, placing it in the top 23.5%.
Is Avalyn Pharma's 3-1 Month Momentum % too high?
Avalyn Pharma's current 3-1 Month Momentum % is -0.37%. Based on the distribution chart, Avalyn Pharma ranks #326 out of 1389 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Avalyn Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's 3-1 Month Momentum % compare to TRAX and IMTX?
According to the Biotechnology industry distribution chart, Avalyn Pharma ranks #326 out of 1389 companies for 3-1 Month Momentum %. This places Avalyn Pharma in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Avalyn Pharma and its competitors. Avalyn Pharma's current 3-1 Month Momentum % is -0.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current 3-1 Month Momentum % of -0.37%. The current 3-1 Month Momentum % is -0.37%. Avalyn Pharma's overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current 3-1 Month Momentum % is -0.37% as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
11GF Score
Get the complete analysis for AVLN
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVLN has been successfully added to your 
